Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Cash (2017 - 2025)

Historic Change in Cash for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Sutro Biopharma's Change in Cash fell 9773.01% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.7 million, marking a year-over-year decrease of 21716.92%. This contributed to the annual value of $121.0 million for FY2024, which is 44975.02% up from last year.
  • Sutro Biopharma's Change in Cash amounted to $1.9 million in Q3 2025, which was down 9773.01% from -$42.2 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Change in Cash ranged from a high of $172.6 million in Q2 2023 and a low of -$153.3 million during Q3 2023
  • Its 5-year average for Change in Cash is -$7.4 million, with a median of -$293000.0 in 2021.
  • In the last 5 years, Sutro Biopharma's Change in Cash plummeted by 2112727.27% in 2021 and then soared by 864808.36% in 2022.
  • Quarter analysis of 5 years shows Sutro Biopharma's Change in Cash stood at -$293000.0 in 2021, then plummeted by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then soared by 225.15% to $15.7 million in 2024, then tumbled by 87.91% to $1.9 million in 2025.
  • Its Change in Cash was $1.9 million in Q3 2025, compared to -$42.2 million in Q2 2025 and -$84.1 million in Q1 2025.